A vaccination session (photo illustration).

-

JOE RAEDLE / GETTY IMAGES NORTH AMERICA / Getty Images via AFP

The cost of the future vaccine being developed by Sanofi and GSK laboratories against Covid-19 "is not yet fully defined", but will be "less than ten euros" per dose, said Olivier Bogillot, president of Sanofi France, this Saturday on France Inter.

"The French and Europeans will have the Sanofi vaccine at the same time as American patients," he said.

“We signed during the summer with the Americans, the same week with the Europeans and with the British,” he summed up: the United States will have around 100 million doses, the Europeans 300 million and the Great Britain 60 million.

For the European part, the vaccine will be manufactured in France, in Vitry-sur-Seine (Val-de-Marne), recalled the manager, welcoming the association of his group with the British GSK for this operation.

"It is not common to partner with a competitor but it is rather healthy in this war against the Covid", he said.

“Millions of doses” will also be supplied to developing countries via the Sepi structure at “quite exceptional” pricing conditions.

Few subcontracting on the side of Sanofi

“We are in the process of measuring all of the production costs that will be ours in the coming months,” said the president of the pharmaceutical company.

"We will be less than ten euros" a dose, he said, welcoming the "sharing of risks with States" which allows prices to be "as low as possible".

Coming back to the price around 2.50 euros per dose announced by the Anglo-Swedish competing laboratory AstraZeneca, Olivier Bogillot explained the difference by the fact that Sanofi uses all its resources "internally", its "own researchers and its own factories. To develop and produce the vaccine, while AstraZeneca "has outsourced production a lot".

Health

Coronavirus: What impact could the pandemic have on the future influenza epidemic?

Society

Coronavirus: "Children rarely get infected and when they do, it does not matter"

  • Health

  • Covid 19

  • Coronavirus

  • epidemic

  • Vaccine

  • Sanofi